Treating Through Drug-Associated Exanthems in Drug Allergy Management: Current Evidence and Clinical Aspects
Jason A Trubiano, Angele Soria, Maria J Torres, Axel Trautmann
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | ELSEVIER | Published : 2021
In the setting of an acute cutaneous adverse drug reaction there is increasing interest in selected phenotypes and hosts to continue drug therapy, especially in settings in which there are limited therapeutic options. This concept of "treating through," defined as the continued use of a drug in the setting of, in particular maculopapular exanthema, potentially avoids unnecessary drug discontinuation. A review of the recent literature, historical viewpoints, and expert opinion are provided within to form recommendations and algorithms for a "treating-through" approach.